Researchers from the USA and Japan evaluated the outcomes of patients with cholangiocellular carcinoma (CCC) undergoing liver transplantation.
A retrospective analysis of all patients with a pathological diagnosis of CCC undergoing liver transplantation was undertaken.
Patients were divided into two groups based on primary tumor location: extrahepatic (EH)-CCC and intrahepatic (IH)-CCC.
The Kaplan-Meier method was used to calculate overall and recurrence-free survival.
|Overall and disease-free survival:|
1 year: 71% and 67%
3 years: 35% and 32%
| Liver Transplantation |
Log-rank analysis was used to determine the significance of prognostic variables.
A total of 25 patients (mean age, 47 years; 14 men) were identified. Of these, 9 patients had EH-CCC (5 patients, Klatskin-type; 2 patients, the middle third; and 2 patients, the distal third) and 16 patients had IH-CCC.
Tumor stage was local (stages I and II; n = 9) or advanced (stages III and IV; n = 16).
Overall and disease-free survival rates were 71% and 67% at 1 year, and 35% and 32% at 3 years, respectively.
Analysis of variables showed statistically significant improved outcomes for the absence of contiguous organ invasion at liver transplantation, small tumor size, and single tumor foci.
Mitsugi Shimoda, of the Dokkyo University School of Medicine, Mibu, Tochigi, Japan, said on behalf of the group, "This study indicates that early survival after liver transplantation for CCC is acceptable."
"Three-year disease-free survival is achieved in approximately 30% of patients.
"These outcomes can be improved by applying strict selection criteria based on prognostic variables identified in this study," it was concluded.